Converting enzyme inhibitors in cardiovascular therapy: current status and future potential

Unger, T.; Gohlke, P.

doi:10.1093/cvr/28.2.146

Cited by 60Renin-Angiotensin System StudiesEicosanoids and Hypertension PharmacologyCoagulation, Bradykinin, Polyphosphates, and Angioedema

Converting enzyme inhibitors in cardiovascular therapy: current status and future potential

Unger, T., Gohlke, P.·1994·Cardiovascular Research

DOI 10.1093/cvr/28.2.146

Open this paper in CoChat — free account

Abstract

Thomas Unger, Peter Gohlke; Converting enzyme inhibitors in cardiovascular therapy: current status and future potential, Cardiovascular Research, Volume 28, Iss

Integrity signals

Registry

Crossref · 10.1093/cvr/28.2.146

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Sorted by citations

Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.
Brink, M., Wellen, J. J., & Delafontaine, P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118698 · Cited by 263 · see citing works
The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data
Dzau, V. J., Bernstein, K. E., Celermajer, D. S., Cohen, J. D., Dahlöf, B., Deanfield, J. E., Dı́ez, J., Drexler, H., Ferrari, R., van Gilst, W. H., et al. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01878-1 · Cited by 260 · see citing works
Self-citation
Estimation of bumblebee queen dispersal distances using sibship reconstruction method
Lepais, O., Darvill, B., O’Connor, S., Osborne, J. L., Sanderson, R., Cussans, J. W., Goffe, L., & Goulson, D. (2010) · Molecular Ecology · doi:10.1111/j.1365-294x.2009.04500.x · Cited by 166 · see citing works
Bradykinin and des-Arg<sup>9</sup>-bradykinin metabolic pathways and kinetics of activation of human plasma
Cyr, M., Lepage, Y., Blais, C., Gervais, N., Cugno, M., Rouleau, J.-L., & Adam, A. (2001) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.2001.281.1.h275 · Cited by 160 · see citing works
“These kinetic characteristics and numerous experimental pieces of evidence, mainly of a pharmacological nature, plead for a role of BK in the cardiovascular and metabolic effects of ACE inhibitors (18, 24, 40).”
Background
Cloning and sequence analysis of a Bothrops jararaca cDNA encoding a precursor of seven bradykinin-potentiating peptides and a C-type natriuretic peptide
Murayama, N., Hayashi, M. A. F., Ohi, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1189 · Cited by 154 · see citing works
Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema Is Characterized by a Slower Degradation of des-Arginine9-Bradykinin
Molinaro, G., Cugno, M., Perez, M., Lepage, Y., Gervais, N., Agostoni, A., & Adam, A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.038067 · Cited by 137 · see citing works
“Angiotensin-converting enzyme inhibitors (ACEi) have been used successfully for 20 years in the treatment of different cardiovascular and metabolic diseases (Unger and Gohlke, 1994).”
Pathophysiologic and Therapeutic Importance of Tissue ACE: A Consensus Report
Dzau, V. J., Bernstein, K. E., Celermajer, D. S., Cohen, J. D., Dahlöf, B., Deanfield, J. E., Dı́ez, J., Drexler, H., Ferrari, R., van Gilst, W. H., et al. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1015709617405 · Cited by 132 · see citing works
“The affinity of ACE inhibitors is, in part, dependent on the binding of the sulfhydryl-, carboxyl-, or phosphinyl-containing group at the N-terminus of the ACE inhibitor with the zinc atom, as well as with the binding of the negatively charged C-terminus of the ACE inhibitor with the postulated positively charged carb…”
BackgroundSelf-citation
A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.
Duan, Q. L., Nikpoor, B., Dubé, M.-P., Molinaro, G., Meijer, I. A., Dion, P., Rochefort, D., Saint-Onge, J., Flury, L., Brown, N. J., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/496899 · Cited by 126 · see citing works
“Angiotensin I–converting enzyme inhibitors (ACEi) are a class of drugs used by 140 million patients worldwide for the treatment of cardiovascular diseases such as hypertension, congestive heart failure, and diabetes (Unger and Gohlke 1994; Brown and Vaughan 1998).”
Background
Bradykinin metabolism and hypotensive transfusion reactions
Cyr, M., Eastlund, T., Blais, C., Rouleau, J. L., & Adam, A. A. (2001) · Transfusion · doi:10.1046/j.1537-2995.2001.41010136.x · Cited by 78 · see citing works
Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin II AT1 Receptor Antagonism on Cardiac Parameters in Left Ventricular Hypertrophy
Zhu, Y., Zhu, Y. Z., Gohlke, P., et al. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00465-7 · Cited by 79 · see citing works
Self-citation
The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats
Sládek, T., Sládková, J., Kolar, F., et al. (1996) · Cardiovascular Research · doi:10.1016/s0008-6363(95)00244-8 · Cited by 75 · see citing works
“The effects of ACE inhibitors are usually abolished by chronic bradykinin receptor blockade, suggesting that angiotensin II may not be involved [ 8 ,26].”
Background
Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: Vessel, organ and species specificity
Metzger, R. P., Franke, F. E., Bohle, R. M., Alhenc‐Gelas, F., & Danilov, S. M. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.12.003 · Cited by 70 · see citing works
Ramipril
Frampton, J. E., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549030-00008 · Cited by 68 · see citing works
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis
Linz, W., Wiemer, G., Schaper, J., et al. (1995) · Molecular and Cellular Biochemistry · doi:10.1007/bf00944788 · Cited by 63 · see citing works
“Consequently ACE inhibitors may exert part of their pharmacological effects via these autocrine-paracrine mechanisms including not only the RAS but also the kallikrein-kinin-system [13, 14].”
BackgroundSelf-citation
Connective Tissue and Repair in the Heart
Weber, K. T., Sun, Y., Katwa, L. C., et al. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb17438.x · Cited by 61 · see citing works
Mechanism & inhibition kinetics of bioassay-guided fractions of Indian medicinal plants and foods as ACE inhibitors
Khan, M. Y., & Kumar, V. (2018) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2018.02.001 · Cited by 60 · see citing works
ACE inhibitor potentiation of bradykinin‐induced venoconstriction
Hecker, M., Blaukat, A., Bara, A. T., et al. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701281 · Cited by 60 · see citing works
“With the exception of captopril (IC50 23 ± 35 nM), the IC50 values of the other ACE inhibitors for the inhibition of ACE activity are virtually identical (1 ± 5 nM) (Unger & Gohlke, 1994).”
Background
Beneficial Effects of Bradykinin on Myocardial Energy Metabolism and Infarct Size
Linz, W., Wiemer, G., & Schölkens, B. A. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00466-9 · Cited by 58 · see citing works
Regression of Chronic Hypoxia-Induced Pulmonary Hypertension, Right Ventricular Hypertrophy, and Fibrosis: Effect of Enalapril
Pelouch, V., Kolář, F., Ošťádal, B., et al. (1997) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007788915732 · Cited by 54 · see citing works
Sacubitril/Valsartan (LCZ696) in Heart Failure
Khder, Y., Shi, V. C., McMurray, J. J. V., & Lefkowitz, M. P. (2016) · Handbook of experimental pharmacology · doi:10.1007/164_2016_77 · Cited by 47 · see citing works
Molecular Imaging of Human ACE-1 Expression in Transgenic Rats
Dilsizian, V., Zynda, T. K., Petrov, A. D., et al. (2012) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2011.10.008 · Cited by 46 · see citing works
ACE Inhibitors Drug Interactions of Clinical Significance
Mignat, C., & Unger, T. (1995) · Drug Safety · doi:10.2165/00002018-199512050-00005 · Cited by 41 · see citing works
Self-citation
Increased angiotensin converting enzyme activity in left ventricular aneurysm of patients after myocardial infarction
Hokimoto, S., Yasue, H., Fujimoto, K., et al. (1995) · Cardiovascular Research · doi:10.1016/s0008-6363(96)88638-x · Cited by 37 · see citing works
Acute adverse reactions associated with angiotensin-converting enzyme inhibitors: genetic factors and therapeutic implications
Nikpoor, B., Duan, Q., & Rouleau, G. A. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.11.1851 · Cited by 29 · see citing works
“In fact, part of the cardiovascular protective role of ACEI drugs results from the vasodilatory effects of BK [16-18].”
Background
Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1receptor?
Fortin, J., Gobeil, F. J., Adam, A. A., et al. (2003) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01124.2002 · Cited by 26 · see citing works
“Because they are vasodilator and natriuretic agents, endogenous kinins may produce a part of the antihypertensive effect of ACE inhibitors, depending on the experimental model (22).”
Background
Attenuation of Reperfusion Arrhythmias by Selective Inhibition of Angiotensin-Converting Enzyme/Kininase II in the Ischemic Zone: Mediated by Endogenous Bradykinin?
Shimada, Y., & Avkiran, M. (1996) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199603000-00017 · Cited by 26 · see citing works
A serious game for traffic accident investigators
BinSubaih, A., Maddock, S., & Romano, D. M. (2006) · Interactive Technology and Smart Education · doi:10.1108/17415650680000071 · Cited by 25 · see citing works
Vasoactive Peptides, their Receptors and Drug Development
Kusserow, H., & Unger, T. (2004) · Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2004.pto940103.x · Cited by 25 · see citing works
Self-citation
Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des‐Arg9‐bradykinin after contact activation
Molinaro, G. A., Adam, A. A., Lepage, Y., Hammerschmidt, D. E., Koenigbauer, U. F., & Eastlund, T. (2002) · Transfusion · doi:10.1046/j.1537-2995.2002.00196.x · Cited by 23 · see citing works
PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction: Study Rationale and Design
The PREAMI Investigators (2000) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1007879201470 · Cited by 19 · see citing works
“T he therapeutic properties of angiotensin-converting enzyme (ACE) inhibitors in cardiovascular disease, such as hypertension and heart failure (HF), have been widely established over the past 15 years [1,2].”
Background
Effects of Sulphydryl-and Non-Sulphydryl-Containing ACE Inhibitors on Left Ventricular Relaxation in the Isolated Guinea Pig Heart
Anning, P. B., Grocott-mason, R. M., & LEWIS, M. J. (1997) · Endothelium · doi:10.3109/10623329709052591 · Cited by 15 · see citing works
The angiotensin AT1 receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling
Hines, J., Fluharty, S. J., & Sakai, R. R. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00662-7 · Cited by 15 · see citing works
Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels
Endlich, K., & Steinhausen, M. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715060-00010 · Cited by 14 · see citing works
Radiopharmaceuticals for Renal Positron Emission Tomography Imaging
Szabó, Z. R., Xia, J., & Mathews, W. B. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.09.008 · Cited by 12 · see citing works
PARM: a practical utility for drug design
Pei, J., Zhou, J., Xie, G., et al. (2001) · Journal of Molecular Graphics and Modelling · doi:10.1016/s1093-3263(00)00104-2 · Cited by 10 · see citing works
A Randomized, Double-Blind, Parallel-Group Study to Compare the Anti-Hypertensive Effects of Imidapril and Nifedipine in the Treatment of Mild-to-Moderate Essential Hypertension
van der Does, R., & Euler, R. (2001) · Journal of International Medical Research · doi:10.1177/147323000102900302 · Cited by 10 · see citing works
MANAGEMENT OF HYPERTENSION AND ITS SEQUELAE WITH ACE INHIBITORS: BIOCHEMICAL, PHARMACOLOGICAL AND CLINICAL ASPECTS
Rangoonwala, B., & Rosenthal, J. (1998) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1998.tb08916.x · Cited by 7 · see citing works
A 24-Week Dose-Titration Study of the Angiotensin-Converting Enzyme Inhibitor Imidapril in the Treatment of Mild-to-Moderate Essential Hypertension in the Elderly
Dews, I. M., & Vandenburg, M. J. (2001) · Journal of International Medical Research · doi:10.1177/147323000102900206 · Cited by 6 · see citing works
Angiotensin Antagonists
Robertson, M. J. (2000) · Journal of Receptors and Signal Transduction · doi:10.3109/10799890009150645 · Cited by 5 · see citing works
Current Trends in Cardiovascular Pharmacology
Ciccone, C. D. (1996) · Physical Therapy · doi:10.1093/ptj/76.5.481 · Cited by 5 · see citing works
Angiotensin‐Converting Enzyme Inhibitors
PETRILLO, E. W. J. (2010) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc174 · Cited by 5 · see citing works
Los inhibidores de la enzima conversora de angiotensina
Barreto, D. G., & Chuckram, A. T. (2014) · Anais Brasileiros de Dermatologia · Cited by 4 · see citing works
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis
Linz, W., Wiemer, G., Schaper, J., et al. (1995) · Springer eBooks · doi:10.1007/978-1-4615-2005-4_12 · Cited by 4 · see citing works
Self-citation
Comparative studies on differential inhibition of the rennin–angiotensin system in the anesthetized guinea pig
Duan, J., Jaramillo, J., Jung, G. L., et al. (1995) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y95-209 · Cited by 4 · see citing works
“observed with exogenously administered bradykinin (Veniant et al. 1992). In this respect, it m y be interesting to note that in a previous study, Bentos et ds (1986) suggested that higher doses of a bradykinin antagonist (M146) might be required to imhibit endogenous rather than exogenous bradykinin.”
Result
ACE Inhibitors: Pharmacology
Gohlke, P., & A., B. (2004) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-18497-0_17 · Cited by 3 · see citing works
Self-citation
Case Study: Moexipril Hydrochloride: A Prodrug of Moexiprilat
Liederer, B. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-49785-3_46 · Cited by 3 · see citing works
Infarct Size as Assessed by Peak Enzyme Levels is Reduced in Patients Who Are Using Angiotensin-Converting Enzyme Inhibitors at the Onset of Infarction
Landmark, K. H., & Aursnes, I. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020060-00004 · Cited by 3 · see citing works
The contribution of angiotensin-converting enzyme (ACE) to the metabolism of kinins (bradykinin and des-Arg9-bradykinin) and effect of ACE inhibitors on their in vitro and in vivo metabolism
Adam, A. A., Blais, C., & Marceau, F. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7579-0_9 · Cited by 3 · see citing works
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: NEW DRUGS IN THE TREATMENT OF HEART FAILURE
Brown, L. (1995) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1995.tb01944.x · Cited by 2 · see citing works
“ACE inhibitors prolong patient survival by preventing or reversing several risk factors for heart failure, including hypertension, hypertrophy, atherosclerosis and insulin resistance (Unger & Gohlke 1994).”
BackgroundResult
Comparison of the antihypertensive effect of imidapril and enalapril in the treatment of mild to moderate essential hypertension: a randomized, double-blind, parallel-group study
van der Does, R., & Euler, R. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80055-2 · Cited by 2 · see citing works
Angiotensin-Converting Enzyme Inhibition after Myocardial Infarction
Zhu, Y. Z., & Lee, H. S. (2000) · Asian Cardiovascular and Thoracic Annals · doi:10.1177/021849230000800125 · Cited by 2 · see citing works
Intracisternally applied angiotensin II does not excite reticulospinal vasomotor neurons in anesthetized rats
Sun, M., & Reis, D. J. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00112-4 · Cited by 2 · see citing works
Empleo del captopril en la determinación de la viabilidad miocárdica en una ventriculografía nuclear
Barreto, D. G. (2014) · Anais Brasileiros de Dermatologia · Cited by 1 · see citing works
A 52-week, open-label, dose-titration safety study of imidapril in the treatment of mild to moderate hypertension
Dews, I. M., & VandenBurg, M. J. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80025-4 · Cited by 1 · see citing works
Clinical Background to the Use of ACE Inhibitor Therapy after Myocardial Infarction
Hall, A. S., & Ball, S. G. (1995) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182679500200503 · Cited by 1 · see citing works
An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension
Sadick, A., Yusuf, M. Z., & Reuter, M. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80070-1
Biochemical and physiological activity of new peptide inhibitors of angiotensin converting enzyme
Гомазков, О. А., Pozdnev, V. F., Kalinina, E. V., et al. (1996) · Bulletin of Experimental Biology and Medicine · doi:10.1007/bf02446574
Treated With Angiotensin-Converting Enzyme Inhibition Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients
Rouleau, J. L., Adam, A. A., Lepage, Y., Gervais, N., Cugno, M., Ji, R., Woolf, C. J., Wang, H., Kohno, T., Brenner, G. J., et al. (2011)
Effects of ovokinin on isolated aortas of guinea pigs, normotensive and spontaneously hypertensive rats
Yim, C. (1998) · VTechWorks (Virginia Tech)
Angiotensin‐Converting Enzyme Inhibitors
PETRILLO, E. W. J. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc174.pub2

Authors: Unger, T., & Gohlke, P.
Affiliations: Heidelberg University (DE)
Corresponding author: Unger, T.
ORCID: Unger, T.
Gohlke, P.
Venue: Cardiovascular Research
Publisher: Oxford University Press (OUP)
Published: 1994-02-01
Volume: 28
Issue: 2
Pages: 146-158
ISSN: 0008-6363 (ISSN-L)
DOI: 10.1093/cvr/28.2.146
OpenAlex: W2126508010
Cited by: 60
References: 0
Citations by year: 2021: 1 · 2018: 1 · 2016: 1 · 2014: 2 · 2012: 1
FWCI: 7.25
Type: journal article
Language: en
Open access: closed
Locations: Cardiovascular Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords: ACE inhibitors, cardiovascular disease treatment, hypertension, antihypertensive drugs, renin-angiotensin system
MeSH terms: Angiotensin-Converting Enzyme Inhibitors, Cardiovascular Diseases, Cardiovascular System, Humans, Peptidyl-Dipeptidase A, Renin-Angiotensin System

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Converting enzyme inhibitors in cardiovascular therapy: current status and future potential

Abstract

Integrity signals

Claims the paper makes

Cited by

Related

Record

About these checks